Wells Center for Pediatric Research/Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children at Indiana University School of Medicine, Indianapolis, Indiana.
Respir Care. 2024 Nov 18;69(12):1587-1591. doi: 10.4187/respcare.12580.
COVID-19, caused by SARS-CoV-2 infection, led to a pandemic of acute respiratory illness that is ongoing. High-flow nasal cannula (HFNC) is a commonly used form of respiratory support during acute respiratory distress and is used to treat patients with COVID-19 in many centers. Due to the novel nature of COVID-19 at the onset of the pandemic, evidence to support the use and best practices of HFNC for treating patients with COVID-19 was lacking. This is a review of key peer-reviewed manuscripts from 2022-2023 discussing the efficacy and best practices for using HFNC for patients with COVID-19. Efficacy of HFNC for COVID-19, the use of the respiratory oxygenation index to guide HFNC for COVID-19, and concerns of generated/fugitive aerosols when using HFNC for COVID-19 are emphasized.
由 SARS-CoV-2 感染引起的 COVID-19 导致了一种持续存在的急性呼吸道疾病大流行。高流量鼻导管（HFNC）是急性呼吸窘迫时常用的呼吸支持形式，在许多中心用于治疗 COVID-19 患者。由于 COVID-19 在大流行初期的新颖性，缺乏支持 HFNC 用于治疗 COVID-19 患者的使用和最佳实践的证据。这是对 2022-2023 年讨论 HFNC 治疗 COVID-19 患者的疗效和最佳实践的主要同行评审手稿的回顾。强调了 HFNC 治疗 COVID-19 的疗效、使用呼吸氧合指数指导 HFNC 治疗 COVID-19 以及使用 HFNC 治疗 COVID-19 时产生/逃逸气溶胶的问题。
